Benny Johnson

6PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.

Kristen Simmons, Jane V Thomas, Kaysia Ludford

|Apr 27, 2023
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.

Van K Morris, Amir Jazaeri, Shannon N Westin

|Aug 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Benny Johnson, Cara L Haymaker, Edwin R Parra

|Aug 10, 2022
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.

Victoria Serpas Higbie, Jane Rogers, Hyunsoo Hwang

|Aug 01, 2022
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.

Alexey V Sorokin, Preeti Kanikarla Marie, Lea Bitner

|Jun 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.

Jenny E Chu, Benny Johnson, Laveniya Kugathasan

Pageof 1

Frequent Collaborators

5 joint publications

Van Karlyle Morris

3 joint publications

Scott Kopetz

2 joint publications

Michael J Overman

2 joint publications

Christine Parseghian